Fortress Biotech, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 0.029 million compared to USD 0.028 million a year ago. Revenue was USD 21.09 million compared to USD 9.48 million a year ago. Net loss was USD 20.78 million compared to USD 15.55 million a year ago. Basic loss per share from continuing operations was USD 0.26 compared to USD 0.2 a year ago. Diluted loss per share from continuing operations was USD 0.26 compared to USD 0.2 a year ago. For the nine months, sales was USD 0.252 million compared to USD 1.04 million a year ago. Revenue was USD 50.52 million compared to USD 31.85 million a year ago. Net loss was USD 33.14 million compared to USD 41.23 million a year ago. Basic loss per share from continuing operations was USD 0.41 compared to USD 0.59 a year ago. Diluted loss per share from continuing operations was USD 0.41 compared to USD 0.59 a year ago.